Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Actuate Therapeutics, Inc. (ACTU)
NASDAQ:ACTU
Holding ACTU?
Track your performance easily
ACTU Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.33 - $10.16
Previous Close$8
Volume2.70K
Average Volume (3M)41.44K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.55
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding21,767,391
10 Day Avg. Volume39,718
30 Day Avg. Volume41,437
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-1.62
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Actuate Therapeutics, Inc. News
ACTU FAQ
What was Actuate Therapeutics, Inc.’s price range in the past 12 months?
Actuate Therapeutics, Inc. lowest stock price was $7.33 and its highest was $10.16 in the past 12 months.
What is Actuate Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Actuate Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Actuate Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Actuate Therapeutics, Inc. overvalued?
According to Wall Street analysts Actuate Therapeutics, Inc.’s price is currently Overvalued.
Does Actuate Therapeutics, Inc. pay dividends?
Actuate Therapeutics, Inc. does not currently pay dividends.
What is Actuate Therapeutics, Inc.’s EPS estimate?
Actuate Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Actuate Therapeutics, Inc. have?
Actuate Therapeutics, Inc. has 19,111,635 shares outstanding.
What happened to Actuate Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Actuate Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACTU
---
Actuate Therapeutics, Inc. Stock Smart Score
Company Description
Actuate Therapeutics, Inc.
Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B. We believe that the blockade of GSK-3B signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. We have exclusively licensed a portfolio of GSK-3 inhibitors developed in a collaboration between the University of Illinois-Chicago (UIC) and Northwestern University (NU).
---
Technical Analysis
TRACON Pharmaceuticals
―
Kintara Therapeutics
―
Cyclacel Pharmaceuticals
―
ADC Therapeutics
―
---